Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company based in Needham, Massachusetts, is currently navigating a quiet phase in the market. The company, listed on the Nasdaq under the ticker symbol CDNT, specializes in the development of oncolytic viral immunotherapies aimed at treating cancer patients. As of December 10, 2025, the closing price of Candel Therapeutics’ stock was $6.47, reflecting a position closer to its 52-week low of $4.25, recorded on April 8, 2025, than its 52-week high of $13.68, achieved on February 19, 2025.
The company’s market capitalization stands at approximately $318.41 million USD, indicating its valuation in the health care sector. Despite its innovative focus, Candel Therapeutics reports a negative price-to-earnings ratio of -12.26, underscoring the absence of positive earnings. This financial metric, coupled with a price-to-book ratio of 3.65, suggests that the market values the company at about three and a half times its book value.
In terms of recent developments, Candel Therapeutics announced a virtual R&D event scheduled for December 5, 2025, as part of its latest public disclosure on November 18, 2025. This event is anticipated to provide insights into the company’s ongoing research and development efforts, which are crucial for its strategic positioning in the competitive landscape of cancer treatment innovations.
The stock’s performance over the past year has exhibited significant volatility, with a nearly three-fold difference between its highest and lowest trading prices. However, the current trading level remains closer to the lower end of this range, reflecting cautious investor sentiment amidst the company’s developmental phase.
As Candel Therapeutics continues to advance its pipeline of oncolytic viral immunotherapies, the upcoming virtual R&D event may serve as a pivotal moment for the company to engage with stakeholders and potentially influence its market trajectory.
